Afamelanotide - Clinuvel Pharmaceuticals
Alternative Names: [Nle4,DPhe7]-alpha-MSH; Afamelanotide acetate; CUV-1647; EPT-1647; Melanotan I; Melanotan™; MT I; PRENUMBRA; Scenesse; Scenesse® EnfanceLatest Information Update: 07 Oct 2024
At a glance
- Originator University of Arizona
- Developer Clinuvel Pharmaceuticals; Winhealth Pharma
- Class Antiacnes; Antineoplastics; Antipyretics; Melanocyte-stimulating hormones; Peptides; Skin disorder therapies; Vascular disorder therapies
- Mechanism of Action Melanocortin type 1 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Erythropoietic protoporphyria
- Phase III Polymorphus light eruptions; Vitiligo
- Phase II Hepatic-porphyria; Pemphigus; Stroke; Xeroderma pigmentosum
- Preclinical Parkinson's disease
- Suspended Urticaria
- Discontinued Acne vulgaris; Actinic keratosis; Photodamage; Squamous cell cancer
Most Recent Events
- 30 Sep 2024 Preregistration for Erythropoietic protoporphyria (Prevention) in Canada (SC)
- 30 Sep 2024 Clinuvel Pharmaceuticals files a New Drug Submission (NDS) to Health Canada, seeking approval for afamelanotide for the prevention of phototoxicity in adult patients with Erythropoietic protoporphyria
- 28 Aug 2024 No recent reports of development identified for preclinical development in Stroke in Australia (Immediate release)